Rituximab Therapy for Severe Cutaneous Leukocytoclastic Angiitis Refractory to Corticosteroids, Cellcept and Cyclophosphamide

We report our clinical experience with rituximab in the treatment of 2 patients with idiopathic cutaneous angiitis who relapsed after Stash Gear treatment with high-dose corticosteroids and cyclophosphamide.A 39-year-old woman and a 51-year-old man presented with ulcerating maculopapular rash in both lower limbs which relapsed 6 months after treatment with a combination of high-dose corticosteroids and cyclophosphamide.After treatment with 2 g of rituximab, the first patient has still been in clinical remission for 32 months while the second has finished 28 months.

Interestingly, CD19 which had dropped to 0.5% 8 months later in both patients.Despite that, our patients Audio Tube are still in clinical remission.

No significant side effects were noted during infusions and up to the period of follow-up.In conclusion, rituximab is a useful and safe agent in the treatment of idiopathic cutaneous angiitis refractory to conventional therapy.Clinical remission persists years after improvement of B-cell suppression.

Leave a Reply

Your email address will not be published. Required fields are marked *